As Crestor generics gear up to battle the brand, AstraZeneca is retrenching with a $1.5 billion restructuring plan.
The London-based drugmaker loses its exclusive on the blockbuster statin drug next week, a long-dreaded event that puts more than one-fifth of its sales at risk. Crestor brought in $5 billion in 2015, making it the company’s biggest seller, and 21% of its full-year sales of $23.6 billion.
So, like other Big Pharmas facing blockbuster patent expiration before it, AstraZeneca raised Crestor’s price in its last months on the market, helping fuel a street-beating $1.16 billion in Q1 sales for the drug. And it’s following up with cost cuts to compensate for the impending loss in revenue.
AstraZeneca will target sales and administrative functions for cuts and continue streamlining its manufacturing network, the company said in a presentation to the media Friday. The aim is to preserve ongoing spending on its pipeline meds and deliver $1.1 billion in annual savings by 2018.
The SG&A cutbacks will push AstraZeneca’s global operations toward sharing back-office services, something that fellow multinational drugmaker Novartis has done with great success. They’ll also hit the sales organization, though few details were available at press time. The restructuring itself will cost $1.5 billion, mostly in cash, AstraZeneca said.
The cost-cutting announcement came as AstraZeneca rolled out first-quarter results, with earnings per share slightly ahead of analyst estimates. Higher-than-expected revenue of $6.1 billion fueled that beat, partly in thanks to an unanticipated milestone payment from Pfizer on Nexium OTC, partly on revved-up sales in diabetes, including Farxiga/Forxiga, which more than doubled to $165 million, and Onglyza, which was up 20% to $211 million. The franchise took a leap in emerging markets as well, with a 65% boost to sales.
Brilinta growth and the Crestor increase also pitched in.
A new indication on Brilinta in the U.S–for longer-term use in ACS patients–helped deliver a 52% hike for the region and new-to-brand prescription share of 12%, the company said.
CEO Pascal Soriot emphasized that Q1 turned out as the company had anticipated, and pointed to the performance in his “growth platforms,” including diabetes and Brilinta. “I was particularly pleased with the results in China, where we continued to deliver double-digit sales growth, and with the progress of our New Oncology launches,” Soriot said, calling out $99 million in sales from the breast cancer med Lynparza, the brand-new lung cancer treatment Tagrisso and Iressa, now approved for first-line use in EGFR-positive lung cancer.
Tagrisso was a particularly good performer with $51 million in sales, Bernstein analyst Tim Anderson pointed out in a Friday investor note.
But certain key products fell short, including Symbicort, which was “especially weak,” Anderson said. Branded Nexium, facing generics and the OTC version, also missed.
Overall, the first-quarter results “remained consistent with the AstraZeneca narrative,” the analyst said.
By Tracy Staton
Source: Fierce Pharma
The company plans to pour more than $500 million in additional funds into its active pharmaceutical ingredient (API) plant in Raheen, Limerick County, the country’s Industrial Development Agency (IDA) said. The new funding brings the company’s total investment in the site to 927 million euros ($1 billion).
“If in 2005 someone told you that two-thirds of our industry would be driven on the R&D side by emerging biopharma—it would be unthinkable. If one were to project that trend forward, what it would suggest is that we could have a day when we do this talk, say in 2027 or 2028, where 80% of the industry’s pipeline is coming from emerging companies.”
The German healthcare and agrochemicals giant told Reuters that in future its pharma pipeline will focus on cardiovascular disease, neurology, rare diseases and immunology, while de-emphasizing women’s health, a field it first focused on with the acquisition of the former women’s health specialist Schering in 2006.